Global Cancer Therapeutics Market

Cancer Therapeutics Market Size, Share, Growth Analysis, By Application(Blood Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer), By Drug(Revlimid, Avastin, Herceptin, Rituxan), By End-User(Hospitals, Specialty Clinics, Cancer and Radiation Therapy Centers), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35H2214 | Region: Global | Published Date: July, 2024
Pages: 157 | Tables: 112 | Figures: 76

Cancer Therapeutics Market Insights

Global Cancer Therapeutics Market size was valued at USD 136.6 Billion in 2022 and is poised to grow from USD 149.02 Billion in 2023 to USD 299.13 Billion by 2031, at a CAGR of 9.1% during the forecast period (2024-2031). 

Growing number of cancer patients around the world are projected to bolster the demand for cancer therapeutics over the coming years. High investments in oncology research and growing demand for better cancer treatments are also expected to generate new opportunities for cancer therapeutics companies going forward. Rising adoption of gene therapies and personalized medicine to treat different cancer indications will also supplement market growth in the future. Growing use of combination therapies and increasing spending by governments to support oncology research are also expected to uplift sales of cancer therapeutics across the study period and beyond. On the other hand, drug resistance, cancer heterogeneity, and adverse side effects of cancer therapeutics are key restraints that trouble cancer therapeutics providers around the world. 

US Cancer Therapeutics Market is poised to grow at a sustainable CAGR for the next forecast year.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Cancer Therapeutics Market size was valued at USD 136.6 Billion in 2022 and is poised to grow from USD 149.02 Billion in 2023 to USD 299.13 Billion by 2031, at a CAGR of 9.1% during the forecast period (2024-2031). 

Cancer therapeutics providers around the world are estimated to focus on research to maximize their business potential and stay competitive. Developing new therapeutics for specific cancer indications will also be a preferred strategy for new as well as leading cancer therapeutics companies. Market players can also benefit from government support to take their oncology research capabilities to the next level. Use of advanced drug discovery and development techniques will also be popular among cancer therapeutics providers in the future. 'Roche Holding AG (Switzerland) ', 'Novartis AG (Switzerland) ', 'Merck & Co., Inc. (USA) ', 'Pfizer Inc. (US) ', 'AstraZeneca plc (UK) ', 'Bristol Myers Squibb Company (USA) ', 'AbbVie Inc. (USA) ', 'Amgen Inc. (USA) ', 'GlaxoSmithKline plc (United Kingdom) ', 'Eli Lilly and Company ', 'Takeda Pharmaceutical Company Limited (Japan) ', 'Sanofi S.A. (France) ', 'Gilead Sciences, Inc. (USA) ', 'Bayer AG (Germany) ', 'Johnson & Johnson USA ', 'AbilityPharma (Spain) ', 'Adcendo (Denmark) ', 'Beroni Group (Australia) ', 'BioAtla (USA) ', 'Astellas Pharma Inc. (Japan)'

Poor lifestyle choices and growing adoption of unhealthy habits have significantly increased the number of people suffering from cancer. This surge in incidence of cancer around the world is a key factor promoting cancer therapeutics demand.  

Use of AI for Drug Discovery: Cancer therapeutics companies can focus on utilization of artificial intelligence in their research to fast-track innovation. Market players can integrate AI technology with their drug discovery and development tools to identify new drug targets and optimize the efficacy of currently used ones. Use of AI in other cancer therapeutics business aspects will also be highly popular in the long run. 

North America is estimated to secure the top spot when it comes to the cancer therapeutics market. Increasing incidence of cancer and high investments in oncology research are forecasted to be the key factors contributing to the dominance of this segment. Availability of proper reimbursement policies and rising demand for novel cancer treatments are also estimated to help this region maintain its high market share. The United States is slated to be the most opportune market for cancer therapeutics companies looking to make an impact in the North American region.   

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Cancer Therapeutics Market

Report ID: SQMIG35H2214

$5,300
BUY NOW GET FREE SAMPLE